What Is Wegovy Called — and Why Does the Name Matter?

Why does semaglutide have three different brand names in the UK?

It is genuinely confusing, and our prescribers hear about it most weeks. A single active molecule (semaglutide) has been developed by Novo Nordisk across several clinical programmes, each with its own dose range, formulation and regulatory approval. UK law ties a medicine's legal use to its specific marketing authorisation, so the brand name is not just a label; it is a shorthand for what the medicine is approved to treat and at what doses.

Ozempic was approved first, as a once-weekly injection for type 2 diabetes. Its approved doses (0.5mg and 1mg) are lower than those used in weight-management trials. Rybelsus followed as an oral tablet for diabetes, at 3mg, 7mg and 14mg. Neither carries a weight-loss authorisation from the MHRA, so a prescriber offering either one as a route to weight management would be stepping outside the medicine's licensed indication. Wegovy, by contrast, was developed at higher doses specifically for obesity and overweight, and holds the weight-management licence.

The practical upshot: if you are looking for a semaglutide-based treatment for weight management, Wegovy is the one your prescriber should be discussing with you. You can explore how semaglutide works as an active ingredient if you want to understand the underlying mechanism before deciding whether it suits you.

What forms does Wegovy come in, and has the name changed recently?

For most of its UK history, Wegovy referred specifically to the weekly subcutaneous injection, a pre-filled pen that delivers semaglutide just beneath the skin of the abdomen, thigh or upper arm. That remains the most established form. The injection pathway starts at 0.25mg, steps up roughly every four weeks through 0.5mg, 1mg and 1.7mg, and reaches a 2.4mg maintenance dose; a higher 7.2mg maximum dose was subsequently approved by the MHRA.

On 11 June 2026 the same brand name extended to a tablet: the MHRA approved an oral Wegovy as the first GLP-1 medicine licensed for weight management in tablet form in the UK. Its dose schedule is entirely different, starting at 1.5mg daily, moving through 4mg and 9mg to a 25mg maintenance dose. Storage is simpler too: unlike the injection, which needs to stay in the fridge, the tablet sits at room temperature and fits easily into a bag or a kitchen shelf, many people find the routine of taking it before the kettle goes on in the morning straightforward to build into a day.

Because the injection and the tablet share the Wegovy name, it is worth being clear which form is being discussed whenever you read about it. If you are curious about what using Wegovy is actually like day to day, that page covers both forms in practical terms.

Does the name Wegovy appear in the US or EU, and is Zepbound the same thing?

Wegovy is used as a brand name in the United States and across much of Europe as well as the UK, so you may see it referenced in international clinical trial reports or news coverage. The underlying medicine is the same semaglutide, though approved doses and pen presentations can differ between regulatory regions. NICE's appraisal of semaglutide for weight management (NICE TA875) covers the UK-specific clinical evidence and commissioning criteria, and is the authoritative reference for how NHS England frames access.

Zepbound is a name that sometimes appears alongside Wegovy in searches. It is not the same medicine: Zepbound is the US brand name for tirzepatide, a different active ingredient made by Eli Lilly. Tirzepatide is sold in the UK under the brand name Mounjaro. Zepbound does not exist as a UK product and cannot be obtained from any UK pharmacy. If you are weighing up the differences between the two medicines, a look at the Wegovy treatment overview and the equivalent Mounjaro information side by side is the clearest way to compare them. The medicine behind Wegovy page goes deeper on the pharmacology for anyone who wants the science.

Does it matter which name a seller uses when advertising weight-loss injections?

Yes, in a practical safety sense. Counterfeits and unlicensed products are sometimes advertised online under the generic name semaglutide or described vaguely as weight-loss injections, precisely because the terminology is murky enough to obscure what is actually being sold. The MHRA has warned publicly about fake pens sold through social media and unofficial websites, some of which have been found to contain insulin rather than semaglutide, a potentially dangerous substitution. Sellers offering these medicines without a prescription, at prices well below the market range, or through unverifiable channels are red flags worth taking seriously.

The safe route is a prescription issued by a GPhC-registered prescriber following a proper clinical assessment. Any UK online pharmacy can be checked on the GPhC pharmacy register, worth doing before you hand over payment details or medical information to anyone. For a fuller picture of what a responsible private service looks like, a bit about how nume works sets out the clinical infrastructure we have in place. If cost is a factor in your thinking, the context around Wegovy pricing in the UK is worth reading before you compare providers on price alone.

If you are ready to find out whether Wegovy is suitable for you, a free consultation with our prescribers is the place to start, reviewed the same day by a real clinician, not software.